المؤلفون: T. Morgunova B., I. Glinkina V., V. Fadeev V., Т. Моргунова Б., И. Глинкина В., В. Фадеев В.

المصدر: Meditsinskiy sovet = Medical Council; № 12 (2021); 220-227 ; Медицинский Совет; № 12 (2021); 220-227 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: diabetes mellitus, treatment, metformin, impaired glucose tolerance, impaired fasting glycemia, сахарный диабет, лечение, метформин, нарушенная толерантность к глюкозе, нарушенная гликемия натощак

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6352/5750; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 9. Сахарный диабет. 2019;22(1S1):1–144. https://doi.org/10.14341/DM221S1.; Dedov I., Shestakova M., Benedetti M.M., Simon D., Pakhomov I., Galstyan G. Prevalence of Type 2 Diabetes Mellitus (T2DM) in the Adult Russian Population (NATION Study). Diabetes Res Clin Pract. 2016;115:90−95. https://doi.org/10.1016/j.diabres.2016.02.010.; Шестакова Е.А., Лунина Е.Ю., Галстян Г.Р., Шестакова М.В., Дедов И.И. Распространенность нарушений углеводного обмена у лиц с различными сочетаниями факторов риска сахарного диабета 2-го типа в когорте пациентов исследования NATION. Сахарный диабет. 2020;23(1):4–11. https://doi.org/10.14341/DM12286.; Дедов И.И., Шестакова М.В. (ред.). Сахарный диабет: диагностика, лечение, профилактика. М.: Медицинское информационное агентство; 2011. 808 c. Режим доступа: https://www.euni.cz/files/fileUploader/download/dia_ru/Textbook_Hibrid%20diabetic%20forms.pdf.; Garber A.J., Handelsman Y., Einhorn D., Bergman D.A., Bloomgarden Z.T., Fonseca V. et al. Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia: When Do the Risks of Diabetes Begin? A Consensus Statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933–946. https://doi.org/10.4158/EP.14.7.933.; Kanat M., DeFronzo R.A., Abdul-Ghani M. Treatment of Prediabetes. World J Diabetes. 2015;6(12):1207–1222. https://doi.org/10.4239/wjd.v6.i12.1207.; Kanat M., Mari A., Norton L., Winnier D., DeFronzo R.A., Jenkinson Ch., Abdul-Ghani M.A. Distinct B-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance. Diabetes. 2012;61(2):447–453. https://doi.org/10.2337/db11-0995.; Abdul-Ghani M., DeFronzo R.A., Jayyousi A. Prediabetes and Risk of Diabetes and Associated Complications: Impaired Fasting Glucose versus Impaired Glucose Tolerance: Does It Matter? Curr Opin Clin Nutr Metab Care. 2016;19(5):394–399. https://doi.org/10.1097/MCO.0000000000000307.; Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., IlanneParikka P. et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med. 2001;344(18):1343–1350. https://doi.org/10.1056/NEJM200105033441801.; Knowler W.C., Barret-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M. Reduction in the Incidence of type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.; Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V. The Indian Diabetes Prevention Programme Shows That Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects with Impaired Glucose Tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297. https://doi.org/10.1007/s00125-005-0097-z.; Diabetes Prevention Program Research Group. Long-Term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications over 15-Year Follow-Up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866–875. https://doi.org/10.1016/S2213-8587(15)00291-0.; Diabetes Prevention Program Research Group. Long-Term Safety, Tolerability, and Weight Loss Associated with Metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–737. https://doi.org/10.2337/dc11-1299.; DeFronzo R.A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 2009;58(4):773–795. https://doi.org/10.2337/db09-9028.; DeFronzo R.A. Insulin Resistance, Lipotoxicity, Type 2 Diabetes and Atherosclerosis: the Missing Links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270–1287. https://doi.org/10.1007/s00125-010-1684-1.; Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118. https://doi.org/10.1056/NEJMra041001.; Spiegelman B.M. PPAR-Gamma: Adipogenic Regulator and Thiazolidinedione Receptor. Diabetes. 1998;47(4):507–514. https://doi.org/10.2337/diabetes.47.4.507.; Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., Mari A., DeFronzo R.A. Thiazolidinediones Improve Beta-Cell Function in Type 2 Diabetic Patients. Am J Physiol Endocrinol Metab. 2007;292(3):E871–E883. https://doi.org/10.1152/ajpendo.00551.2006.; DeFronzo R.A., Tripathy D., Schwenke D.C., Banerji M.A., Bray G.A., Buchanan T.A. et al. Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. N Engl J Med. 2011;364(12):1104–1115. https://doi.org/10.1056/NEJMoa1010949.; Espinoza S.E., Wang C.P., Tripathy D., Clement S.C., Schwenke D.C., Banerji M.A. et al. Pioglitazone Is Equally Effective for Diabetes Prevention in Older versus Younger Adults with Impaired Glucose Tolerance. AGE. 2016;38(5–6):485–493. https://doi.org/10.1007/s11357-016-9946-6.; Tripathy D., Schwenke D.C., Banerji M.A., Bray G.A., Buchanan T.A., Clement S.C. et al. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. Clin Endocrinol Metab. 2016;101(5):2056–2062. https://doi.org/10.1210/jc.2015-4202.; Berkowitz K., Peters R., Kjos S.L., Goico J., Marroquin A., Dunn M.E. et al. Effect of Troglitazone on Insulin Sensitivity and Pancreatic Beta-Cell Function in Women at High Risk for NIDDM. Diabetes. 1996;45(11):1572–1579. https://doi.org/10.2337/diab.45.11.1572.; Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C. et al. Effect of Pioglitazone on Pancreatic Beta-Cell Function and Diabetes Risk in Hispanic Women with Prior Gestational Diabetes. Diabetes. 2006;55(2): 517–522. https://doi.org/10.2337/diabetes.55.02.06.db05-1066.; Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J. et al. Preservation of Pancreatic Beta-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Diabetes. 2002;51(90:2796–2803. https://doi.org/10.2337/diabetes.51.9.2796.; Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care. 2004;27(1):155–161. https://doi.org/10.2337/diacare.27.1.155.; Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for Prevention of Type 2 Diabetes Mellitus: the STOP-NIDDM Randomised Trial. Lancet. 2002;359(9323):2072–2077. https://doi.org/10.1016/S0140-6736(02)08905-5.; Kawamori R., Tajima N., Iwamoto Y., Kashiwagi A., Shimamoto K., Kaku K. Voglibose for Prevention of Type 2 Diabetes Mellitus: A Randomised, DoubleBlind Trial in Japanese Individuals with Impaired Glucose Tolerance. Lancet. 2009;373(9675):1607–1614. https://doi.org/10.1016/S0140-6736(09)60222-1.; DeFronzo R.A., Abdul-Ghani M. Type 2 Diabetes Can Be Prevented with Early Pharmacological Intervention. Diabetes Care. 2011;34(2 Suppl):S202–S209. https://doi.org/10.2337/dc11-s221.; Slack E., Hapfelmeier S., Stecher B., Velykoredko Y., Stoel M., Lawson M.A. et al. Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism. Science. 2009;325(5940):617–620. https://doi.org/10.1126/science.1172747.; Le Roux C.W., Astrup A., Fujioka K., Greenway F., Lau D., Gaal L.C. et al. 3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial. Lancet. 2017;389(10077):1399–1409. https://doi.org/10.1016/S0140-6736(17)30069-7.; Armato J.P., DeFronzo R.A., Abdul-Ghani M., Ruby R.J. Successful Treatment of Prediabetes in Clinical Practice Using Physiological Assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018;6(10):781–789. https://doi.org/10.1016/S2213-8587(18)30234-1.; Abdul-Ghani M.A., Stern M.P., Lyssenko V., Tuomi T., Groop L., Defronzo R.A. Minimal Contribution of Fasting Hyperglycemia to the Incidence of Type 2 Diabetes in Subjects with Normal 2-h Plasma Glucose. Diabetes Care. 2010;33(3):557–561. https://doi.org/10.2337/dc09-1145.; Cowie C.C., Harris M.I., Silverman R.E., Johnson E.W., Rust K.F. Effect of Multiple Risk Factors on Differences between Blacks and Whites in the Prevalence of Non-Insulin-Dependent Diabetes Mellitus in the United States. Am J Epidemiol 1993;137(7):719–732. https://doi.org/10.1093/oxfordjournals.aje.a116732.; Jarrett R.J., Keen H., McCartney P. The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabet Med. 1984;1(4):279–283. https://doi.org/10.1111/j.1464-5491.1984.tb01973.x.; Eriksson K.F., Lindgärde F. Prevention of Type 2 (Non-Insulindependent) Diabetes Mellitus by Diet and Physical Exercise. The 6-Year Malmö Feasibility Study. Diabetologia. 1991;34(12):891–898. https://doi.org/10.1007/BF00400196.; Ryder R.E.J. Real-World Diabetes Prevention: From Theory to Practice. Lancet Diabetes Endocrinol. 2018;6(10):756–757. https://doi.org/10.1016/S2213- 8587(18)30267-5.; Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N. et al. Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomised Controlled Trial. Lancet. 2006;368(9541):1096–1105. https://doi.org/10.1016/S0140-6736(06)69420-8.; Knowler W.C., Hamman R.F., Edelstein S.L., Barrett-Connor E., Ehrmann D.A., Walker E.A. Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54(4):1150–1156. https://doi.org/10.2337/diabetes.54.4.1150.; Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., DeFronzo R.A. Beta-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis. J Clin Endocrinol Metab. 2005;90(1):493–500. https://doi.org/10.1210/jc.2004-1133.; Abdul-Ghani M.A., Tripathy D., DeFronzo R.A. Contributions of Beta-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose. Diabetes Care. 2006;29(5):1130– 1139. https://doi.org/10.2337/diacare.2951130.; Abdul-Ghani M.A., Jenkinson C.P., Richardson D.K., Tripathy D., DeFronzo R.A. Insulin Secretion and Action in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance: Results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55(5):1430–1435. https://doi.org/10.2337/db05-1200.; Weyer C., Tataranni P.A., Bogardus C., Pratley R.E. Insulin Resistance and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose Tolerance during Each Stage of Type 2 Diabetes Development. Diabetes Care. 2001;24(1):89–94. https://doi.org/10.2337/diacare.24.1.89.; Abdul-Ghani M.A., Lyssenko V., Tuomi T., DeFronzo R.A., Groop L. Fasting versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study. Diabetes Care. 2009;32(2):281–286. https://doi.org/10.2337/dc08-1264.; Khetan A.K., Rajagopalan S. Prediabetes. Can J Cardiol. 2018;34(5):615–623. https://doi.org/10.1016/j.cjca.2017.12.030.; Brannick B., Dagogo-Jack S. Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. Endocrinol Metab Clin North Am. 2018;47(1):33–50. https://doi.org/10.1016/j.ecl.2017.10.001.; Wasserman D.H., Wang T.J., Brown N.J. The Vasculature in Prediabetes. Circ Res. 2018;122(8):1135–1150. https://doi.org/10.1161/CIRCRESAHA. 118.311912.; Perreault L., Temprosa M., Mather K.J., Horton E., Kitabchi A., Larkin M. et al. Regression from Prediabetes to Normal Glucose Regulation Is Associated with Reduction in Cardiovascular Risk: Results from the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2014;37(9):2622–2631. https://doi.org/10.2337/dc14-0656.; Yakubovich N., Gerstein H.C. Is Regression to Normoglycaemia Clinically Important? Lancet. 2012;379(9833):2216–2218. https://doi.org/10.1016/S0140-6736(12)60828-9.; Perreault L., Pan Q., Schroeder E.B., Kalyani R.R., Bray G.A., Dagogo-Jack S. et al. Regression from Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care. 2019;42(9):1809–1815. https://doi.org/10.2337/ dc19-0244.; Vistisen D., Kivimäki M., Perreault L., Hulman A., Witte D.R., Brunner E.J. et al. Reversion from Prediabetes to Normoglycaemia and Risk of Cardiovascular Disease and Mortality: the Whitehall II Cohort Study. Diabetologia. 2019;62(8):1385–1390. https://doi.org/10.1007/s00125-019-4895-0.; https://www.med-sovet.pro/jour/article/view/6352

الاتاحة: https://www.med-sovet.pro/jour/article/view/6352
https://doi.org/10.21518/2079-701X-2021-12-220-227

المؤلفون: I. Glinkina V., A. Balashova V., A. Shyman S., A. Oderij V., S. Khan A., G. Runova E., T. Morgunova B., V. Fadeev V., И. Глинкина В., А. Балашова В., А. Шыман С., А. Одерий В., С. Хан А., Г. Рунова Е., Т. Моргунова Б., В. Фадеев В.

المصدر: Meditsinskiy sovet = Medical Council; № 7 (2021); 56-67 ; Медицинский Совет; № 7 (2021); 56-67 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: elderly patient, type 2 diabetes, geriatric syndromes, polypharmacy, deprescribing, hypoglycaemia, DPP-4 inhibitors, vildagliptin, пожилой пациент, сахарный диабет 2-го типа, гериатрические синдромы, полипрагмазия, депрескрай-бинг, гипогликемия, ингибиторы ДПП-4, вилдаглиптин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6142/5592; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., Фролова Е.В., Наумов А.В., Воробьева Н.М. и др. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;(1):11-46. doi:10.37586/2686-8636-1-2020-11-46.; American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(1 Suppl.):S168-S179. doi:10.2337/dc21-S012.; Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144-159. doi:10.14341/DM9686.; LeRoith D., Biessels G.J., Braithwaite S.S., Casanueva F.F., Draznin B., Halter J.B. et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5): 1520-1574. doi:10.1210/jc.2019-00198.; Yakaryilmaz F.D., Ozturk Z.A. Treatment of Type 2 Diabetes Mellitus in the Elderly. World J Diabetes. 2017;8(6):278-285. doi:10.4239/wjd.v8.i6.278.; Kim K.S., Park S.W., Cho Y.W., Kim S.K. Higher Prevalence and Progression Rate of Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2018;42(3):224-232. doi:10.4093/dmj.2017.O065.; Jitraknatee J., Ruengorn C., Nochaiwong S. Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A CrossSectional Study in Primary Care Practice. Sci Rep. 2020;10(1):1-10. doi:10.1038/s41598-020-63443-4.; Russo G.T., De Cosmo S., Viazzi F., Mirijello A., Ceriello A., Guida P. et al. Diabetic Kidney Disease in the Elderly: Prevalence and Clinical Correlates. BMCGeriatr. 2018;18(1):1-11. doi:10.1186/s12877-018-0732-4.; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом 9-й выпуск. Сахарный Диабет. 2019;22(1 Suppl.)1-144. doi:10.14341/DM221S1.; Bauduceau B., Le Floch J.P., Halimi S., Verny C., Doucet J. Cardiovascular Complications over 5 Years and Their Association with Survival in the GERODIAB Cohort of Elderly FRENCH Patients with Type 2 Diabetes. Diabetes Care. 2018;41(1):156-162. doi:10.2337/dc17-1437.; Schernthaner G., Schernthaner- Reiter M.H. Diabetes in the Older Patient: Heterogeneity Requires Individualisation of Therapeutic Strategies. Diabetologia. 2018;61(7):1503–1516. doi:10.1007/s00125-018-4547-9.; Longo M., Bellastella G., Maiorino M.I., Meier J.J., Esposito K., Giugliano D. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Front Endocrinol (Lausanne). 2019;10:45. doi:10.3389/fendo.2019.00045.; McCoy R.G., Lipska K.J., Yao X., Ross J.S., Montori V.M., Shah N.D. Intensive Treatment and Severe Hypoglycemia among Adults with Type 2 Diabetes. JAMA Intern Med. 2016;176(7):969-978. doi:10.1001/jamainternmed.2016.2275.; Zeyfang A., Patzelt- Bath A. Importance of Geriatric Syndromes in Older Patients with Diabetes with de novo Insulin Treatment: The VEGAS StudyDrugs Real World Outcomes. 2015;2(1):73–79. doi:10.1007/s40801-015-0014-9.; Ates Bulut E., Soysal P., Isik A.T. Frequency and Coincidence of Geriatric Syndromes According to Age Groups: Single-Center Experience in Turkey between 2013 and 2017. Clin IntersAging. 2018;13:1899-1905. doi:10.2147/CIA.S180281.; Gupta D., Kaur G., Gupta J.A. Geriatric Syndromes. In: Progress in Medicine 2016 (Medicine Update 2016). Vol. 26. New Delhi: Jaypee Brothers; 2016, pp. 1753-1758.; Ткачева О.Н., Фролова Е.В., Яхно Н.Н. Гериатрия. Национальное руководство. М.: ГЭОТАР-Медиа; 2019. 608 с.; Lewandowicz A., Skowronek P., Maksymiuk-Ktos A., Pietkiewicz P. The Giant Geriatric Syndromes Are Intensified by Diabetic Complications. Gerontol Geriatr Med. 2018;4:2333721418817396. doi:10.1177/2333721418817396.; Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения. М.: ГБОУ ДПО РМАПО; 2016. 249 с. Режим доступа: http://irbis.rmapo.ru/UploadsFilesForIrbis/d5d7f99fb18dcb53a8f26f79dc33f17a.pdf.; Сычев Д.А., Бордовский С.П., Данилина К.С., Ильина Е.С. Потенциально не рекомендованные лекарственные средства для пациентов пожилого и старческого возраста: STOPP/START критерии. Клиническая фармакология и терапия. 2016;25(2):76-81. Режим доступа: https://clinpharm-journal.ru/articles/2016-2/potentsialno-nerekomendovannye-lekarstvennye-sredstva-dlya-patsientov-pozhilogo-i-starcheskogo-vozrasta-stopp-start-kriterii/?en=1.; Pham C.B., Dickman R.L. Minimizing Adverse Drug Events in Older Patients. Am Fam Physician. 2007;76(12):1837-1844. Available at: https://pubmed.ncbi.nlm.nih.gov/18217523/.; Fixen D.R. 2019 AGS Beers Criteria for Older Adults. Pharmacy Today. 2019;25(11):42-54. doi:10.1016/j.ptdy.2019.10.022.; O'Mahony D., O'Sullivan D., Byrne S., O'Connor M.N., Ryan C., Gallagher P. STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 2. Age Ageing. 2015;44(2):213-218. doi:10.1093/ageing/afu145.; Lipska K.J., Ross J.S., Miao Y., Shah N.D., Lee S.J., Steinman M.A. Potential Overtreatment of Diabetes Mellitus in Older Adults with Tight Glycemic Control. JAMA Intern Med. 2015;175(3):356-362. doi:10.1001/jamainternmed.2014.7345.; Ткачева О.Н., Остроумова О.Д., Котовская Ю.В., Краснов П.С., Кочетков А.И., Переверзев А.П. Депрескрайбинг сахароснижающих препаратов у пациентов пожилого и старческого возраста: современное состояние вопроса и обзор доказательной базы. Клиническая фармакология и терапия. 2019;28(3):62-67. doi:10.32756/0869-5490-2019-3-62-67.; Reeve E., Denig P., Hilmer S.N., Ter Meulen R. The Ethics of Deprescribing in Older Adults. J Bioeth Inq. 2016;13(4):581-590. doi:10.1007/s11673-016-9736-y.; Farrell B., Black C., Thompson W., McCarthy L., Rojas-Fernandez C., Lochnan H. et al. Deprescribing Antihyperglycemic Agents in Older Persons: Evidence-Based Clinical Practice Guideline. Can Fam Physician. 2017;63(11):832-843. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685444/.; Ligthelm R.J., Kaiser M., Vora J., Yale J.F. Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care. J Am Geriatr Soc. 2012;60(8): 1564-1570. doi:10.1111/j.1532-5415.2012.04055.x.; Snell-Bergeon J.K., Wadwa R.P. Hypoglycemia, Diabetes, and Cardiovascular Disease. Diabetes Technol Ther. 2012;(14 Suppl.):S51-S58. doi:10.1089/dia.2012.0031.; Goto A., Arah O.A., Goto M., Terauchi Y., Noda M. Severe Hypoglycaemia and Cardiovascular Disease: Systematic Review and Meta-Analysis with Bias Analysis. BMJ. 2013;347:f4533. doi:10.1136/bmj.f4533.; Heller S.R., Bergenstal R.M., White W.B., Kupfer S., Bakris G.L., Cushman W.C. et al. Relationship of Glycated Haemoglobin and Reported Hypoglycaemia to Cardiovascular Outcomes in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome Events: The EXAMINE Trial. Diabetes Obes Metab. 2017;19(5):664-671. doi:10.1111/dom.12871.; The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358: 2545-2559. doi:10.1056/NEJMoa0802743.; Hanefeld M., Monnier L., Schnell O., Owens D. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIn and Other Cardiovascular Trials. Diabetes Ther. 2016;7(2):187-201. doi:10.1007/s13300-016-0153-3.; Seidu S., Kunutsor S.K., Topsever P., Hambling C.E., Cos F.X., Khunti K. Deintensification in Older Patients with Type 2 Diabetes: A Systematic Review of Approaches, Rates and Outcomes. Diabetes Obes Metab. 2019;21(7):1668-1679. doi:10.1111/dom.13724.; Haas L.B. Special Considerations for Older Adults with Diabetes Residing in Skilled Nursing Facilities. Diabetes Spectr. 2014;27(1):37-43. doi:10.2337/diaspect.27.1.37.; Мисникова И.В., Ковалева Ю.А., Исаков М.А., Древаль А.В. Структура сахароснижающей терапии в особых группах пациентов с сахарным диабетом 2-го типа на основании данных регистра Московской области. Сахарный диабет. 2019;22(3):206-216. doi:10.14341/DM10084.; Yamamoto-Honda R., Takahashi Y., Mori Y., Yamashita S., Yoshida Y., Kawazu S. et al. Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). Intern Med. 2018;57(9):1229-1240. doi:10.2169/internalmedicine.9481-17.; Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D. et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129-139. doi:10.1056/NEJMoa0808431.; Heller S.R. A summary of the ADVANCE Trial. Diabetes Care. 2009;(32 Suppl.): S357-S361. doi:10.2337/dc09-S339.; American Diabetes Association. Standards of Medical Care in Diabetes 2010. Diabetes Care. 2010;(33 Suppl.):S11-S61. doi:10.2337/dc10-S011.; Black C.D., Thompson W., Welch V., McCarthy L., Rojas-Fernandez C., Lochnan H. et al. Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review. Diabetes Ther. 2017;8(1):23-31. doi:10.1007/s13300-016-0220-945.; Bohannon N. Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice. Postgrad Med. 2009;121(1):40-45. doi:10.3810/pgm.2009.01.1953.; Сидоров А.В. Клиническая фармакология ингибиторов дипептидилпепти-дазы 4: сравнительный обзор. Эффективная фармакотерапия. 2020;16(25):24-48. doi:10.33978/2307-3586-2020-16-25-24-48.; Rathmann W., Kostev K., Gruenberger J.B., Dworak M., Bader G., Giani G. Treatment Persistence, Hypoglycaemia and Clinical Outcomes in Type 2 Diabetes Patients with Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas: A Primary Care Database Analysis. Diabetes Obes Metab. 2013;15(1):55-61. doi:10.1111/j.1463-1326.2012.01674.x.; Gitt A.K., Bramlage P., Binz C., Krekler M., Deeg E., Tschope D. Prognostic Implications of DPP-4 Inhibitor vs. Sulfonylurea Use on Top of Metformin in a Real World Setting - Results of the 1 Year Follow-Up of the Prospective DiaRegis Registry. Int J Clin Pract. 2013;67(10):1005-1014. doi:10.1111/ijcp.12179.; Strain W.D., Lukashevich V., Kothny W., Hoellinger MJ., Paldanius P.M. Individualised Treatment Targets for Elderly Patients with Type 2 Diabetes Using Vildagliptin Add-On or Lone Therapy (INTERVAL): A 24 Week, Randomised, Double-Blind, Placebo-Controlled Study. Lancet. 2013;382(9890):409-416. doi:10.1016/S0140-6736(13)60995-2.; Russo E., Penno G., Del Prato S. Managing Diabetic Patients with Moderate or Severe Renal Impairment Using DPP-4 Inhibitors: Focus on Vildagliptin. Diabetes Metab Syndr Obes. 2013;6:161-170. doi:10.2147/DMSO.S28951.; Matthews D.R., Paldanius P.M., Proot P., Chiang Y.T., Stumvoll M., Del Prato S. Glycaemic Durability of an Early Combination Therapy with Vildagliptin and Metformin versus Sequential Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes (VERIFY): A 5-Year, Multicentre, Randomised, Double-Blind Trial. Lancet. 2019;394(10208):1519-1529. doi:10.1016/S0140-6736(19)32131-2.; Krishnaswami A., Steinman M.A., Goyal P., Zullo A.R., Anderson T.S., Birtcher K.K. et al. Geriatric Cardiology Section Leadership Council, American College of Cardiology. Deprescribing in Older Adults with Cardiovascular Disease. J Am Coll Cardiol. 2019;73(20):2584-2595. doi:10.1016/j.jacc.2019.03.467.53.; Watts N.B., Bilezikian J.P., Usiskin K., Edwards R., Desai M., Law G. et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016;101(1):157-166. doi:10.1210/jc.2015-3167.; https://www.med-sovet.pro/jour/article/view/6142

الاتاحة: https://www.med-sovet.pro/jour/article/view/6142
https://doi.org/10.21518/2079-701X-2021-7-56-67